Share This Page
Drugs in ATC Class C02DB
✉ Email this page to a colleague
Drugs in ATC Class: C02DB - Hydrazinophthalazine derivatives
ATC C02DB Hydrazinophthalazine derivatives: Market dynamics and patent landscape
ATC Class C02DB (hydrazinophthalazine derivatives) is concentrated in a small set of legacy antihypertensive agents. The patent landscape is largely dictated by older composition-of-matter and formulation patents that have mostly aged out in major markets, leaving device and process improvements, line-extension formulations, and limited method-of-use coverage as the main residual IP barriers. Market dynamics are dominated by generic penetration, guideline-driven selection of newer, better-tolerated antihypertensives, and cross-class substitution (thiazides, ACE inhibitors, ARBs, calcium-channel blockers).
Bottom line: expect low pricing power, high generic share, and patent-driven value pockets limited to specific formulations or manufacturing/process steps rather than platform exclusivity.
Which hydrazinophthalazine derivatives are in ATC Class C02DB?
ATC C02DB is an antihypertensive class that historically includes hydrazinophthalazine derivatives, primarily represented in practice by hydralazine-class molecules and closely related phthalazine hydrazine scaffolds depending on country coding conventions. In most payer and formulary systems, the clinical footprint aligns with hydralazine and a limited set of regional legacy equivalents.
Key commercial members tracked in formularies
- Hydralazine (generic-first in most countries; brand remnants in some geographies)
- Other hydrazinophthalazine derivatives that appear in select national coding systems but show minimal global scale compared with hydralazine.
Market implication: where the active is hydralazine or a near-equivalent, patent-driven friction is typically low because generics are entrenched.
What patents protect ATC C02DB (hydrazinophthalazine derivatives) in the US and Europe?
Featured answer: Most protection for hydrazinophthalazine derivatives was historically anchored in composition-of-matter and early pharmaceutical formulation patents. For active ingredients with long market history, those core patents are typically expired or close to expiration, shifting the remaining legal risk to secondary patents (solids, release profile changes, salts, polymorphs, and manufacturing/process claims).
Typical patent categories that show up for C02DB
- Composition of matter
- parent hydrazinophthalazine scaffold or specific substitutions
- salts and solvates
- Pharmaceutical compositions
- tablet/capsule compositions, excipient systems
- particle size and dissolution profile controls
- Manufacturing processes
- granulation, milling, drying conditions
- polymorph control steps
- Method of use
- dosing regimens
- combinations (often with diuretics or other antihypertensives)
- Crystalline forms / polymorphs
- if a specific form was secured late in the product life cycle
Practical legal takeaway
- If the active ingredient is already generic, late-stage “evergreening” tends to be narrow and claim-dependent.
- Process and polymorph patents create manufacturing/IP barriers, not necessarily “regulatory exclusivity” barriers.
- If there is no active Orange Book listing or in-force composition claims, Paragraph IV leverage is weak.
What is the Orange Book status of hydrazinophthalazine derivatives (C02DB)?
Featured answer: For most widely used members of C02DB (especially where clinical use is dominated by hydralazine), Orange Book coverage is usually limited and time-limited, with many listings already expired. Where listings remain, they are usually for formulations or secondary changes rather than the active molecule itself.
How to interpret Orange Book listings for this class
- If the Orange Book shows only expired patents for the listed drug, new entrants face minimal patent delay risk.
- If there is a small number of active formulation patents, the generic risk concentrates on:
- excipient and dissolution specifications
- release characteristics (IR vs ER)
- particle size or solid-state controls
When do patents for hydrazinophthalazine derivatives lose exclusivity in key markets?
Featured answer: For legacy hydrazinophthalazine actives, core exclusivity is largely exhausted. Remaining patent “runway” is typically driven by secondary IP that can extend enforcement for specific formulations or manufacturing conditions, but it rarely matches the scale of modern antihypertensive portfolios.
Timeline mechanics for the class
- Composition patents: mostly expired (long product history)
- Formulation patents: expiry varies by product and filing year
- Patents on manufacturing steps: staggered and claim-limited
Market entry impact
- In the US, expected generic launches generally proceed unless:
- a specific formulation is still protected with active Orange Book patents, or
- a later-filed patent is asserted and successfully enjoined.
- In Europe, enforcement turns on EP family scope, claim breadth, and national validation, but for legacy molecules the biggest barrier is usually not PI.
How strong is the patent estate for ATC C02DB drugs?
Featured answer: The patent estate strength for ATC C02DB is typically low-to-moderate in the aggregate because:
- foundational patents are old
- generic competition is established
- residual IP is narrow and often formulation/process-specific
Patent strength drivers
- Claim scope breadth: narrow claims around particle size or process parameters reduce generic entry barriers.
- Number of active families: low counts translate to a smaller litigation map.
- Jurisdiction coverage: if EP/US coverage is weak, enforcement leverage drops.
- Manufacturing feasibility: process/polymorph claims can be designed around, especially for solid oral drugs.
What generic entry risks exist for hydrazinophthalazine derivatives?
Featured answer: Generic entry risk is typically event-driven:
- a generic must clear whatever active secondary patents exist for the specific dosage form
- otherwise, it behaves like a normal generic clearance pathway
Risk hotspots
- Same dosage form, same release profile: if the branded product is IR tablet with an active formulation patent, risk concentrates there.
- Switching to a different solid-state or excipient strategy: often reduces infringement risk but must meet dissolution/bioequivalence.
- Combination products: if a branded product uses a protected combination or dosing regimen, risk increases.
How does the patent landscape for C02DB compare with other antihypertensive classes?
Featured answer: C02DB’s patent landscape is structurally weaker than newer antihypertensive platforms (ARBs, ACE inhibitors, newer renin-angiotensin pathway agents, SGLT2-inhibitor combinations where relevant).
Why C02DB is different
- Older actives have:
- fewer late-stage breakthroughs
- less “blockbuster-style” line extension
- more prior generic footprints
Commercial consequence
- Lower average contract leverage for licensors
- Faster price compression after the last secondary patent falls
- Limited value in broad licensing unless a specific formulation or ER/alternative solid-state profile remains protected
What patent litigation affects hydrazinophthalazine derivatives (C02DB)?
Featured answer: Litigation for C02DB actives is uncommon at a global scale once generics dominate, though individual cases can occur around:
- an asserted formulation patent
- a polymorph/process patent
- a combination product
How to read litigation for this class
- If there is a standing injunction tied to an Orange Book-listed patent, expect:
- a temporary hold on generic distribution
- subsequent design-arounds or negotiated settlements
- If litigation is absent, market entry is typically fast, with pricing driven by competition.
How do settlement agreements and licensing deals typically work for C02DB?
Featured answer: Where settlements exist in legacy antihypertensives, they often function as:
- partial market-sharing
- delayed launch for a specific strength/dosage form
- explicit design-around commitments
Commercial pattern
- Settlements are more likely when:
- there is an active formulation patent
- a generic cannot quickly change excipient or release profile
- Settlements are less likely when:
- active claims are weak or easily designed around
- the product’s market is small, limiting leverage
What formulations are protected by C02DB patents?
Featured answer: Remaining formulation protection tends to cover solid oral dosage details:
- tablet excipient systems
- granulation and drying parameters
- dissolution targets and particle size ranges
- sometimes ER/modified-release adaptations if they were patented separately
Dosage forms that can carry secondary IP
- Immediate-release tablets
- Oral solids with specific dissolution specifications
- Any modified-release platform (if present in a given geography)
What method-of-use patents exist for hydrazinophthalazine derivatives?
Featured answer: Method-of-use patents, when they exist, usually relate to:
- specific dosing regimens
- combination therapy schedules
- particular patient subsets (limited scope)
Infringement mechanics
- Method claims are typically harder for generics to trigger unless:
- the label is aligned with the patented regimen, and
- evidence supports use consistent with the method claim
How do FDA regulatory milestones and exclusivity affect C02DB entry?
Featured answer: For C02DB legacy actives, exclusivity is typically not the driver. Market entry is governed mainly by:
- the expiration status of patents listed in Orange Book
- the generic’s ability to comply with label and bioequivalence requirements
- potential stays/enforcement from patent litigation
Pathway implications
- Generic oral solids commonly use abbreviated pathways (ANDA) where applicable.
- If there is a protected formulation, the generic faces the patent carve-outs or Paragraph IV procedural steps where patents are listed and active.
Which companies hold the patent rights and commercial brands for C02DB?
For a precise, litigation-grade answer, this requires verified mappings of:
- Orange Book listings by NDC
- EP/US patent family assignees
- label history and product continuity across jurisdictions
Without that verified dataset in the record available here, no defensible company-to-patent attribution can be stated without risking incorrect legal conclusions.
Market dynamics: pricing, supply, demand, and competitive landscape for C02DB
Featured answer: The class behaves like other mature, generic-dominated antihypertensives: high substitution, pricing pressure, and low innovation premium.
Demand drivers
- Hypertension prevalence is stable.
- C02DB molecules are typically used in settings where:
- rapid vasodilation is needed (historically for acute care in some markets)
- other classes are contraindicated or insufficient
- In chronic therapy, substitution by newer classes limits premium pricing.
Supply and competition
- Multi-generic supply reduces price.
- Any remaining branded leverage is usually narrow (specific formulations, channel-specific contracts, or institutional tenders).
Revenue exposure
- Brand owners’ revenue exposure is tied to:
- number of strengths still sold under branded label
- persistence of secondary formulation patents (if any)
- institutional contracts that slow generic substitution
Key takeaways
- C02DB hydrazinophthalazine derivatives are generic-dominated with limited residual IP usually concentrated in secondary formulation or process patents.
- Patent estate strength is typically low-to-moderate because legacy composition claims are mostly expired and enforceable scope is narrow.
- Generic entry risk is event-driven and concentrated in the specific dosage form aligned with any remaining active formulation patents.
- Market dynamics follow the class pattern: substitution, price compression, and limited branded durability unless a specific protected formulation or manufacturing step remains in-force.
FAQs
1) What drives generic pricing for hydrazinophthalazine derivatives in mature markets?
Generic penetration, multi-supplier availability, and channel substitution from first-line antihypertensives.
2) Do polymorph or solid-state patents meaningfully block generic entry for C02DB?
They can block specific manufacturing routes if claims are narrow but technically hard to design around; impact depends on claim scope and whether the generic can change solid-state characteristics without losing performance.
3) Are combination therapy regimens a common patent battleground in C02DB?
Yes when there are method-of-use or combination composition claims still active for specific dosing schedules or combination products.
4) What is the highest-value litigation target in C02DB if patents remain?
The dosage form mapped to the remaining active formulation patents, especially if dissolution or excipient specs are claim-limited but central to infringement.
5) How do FDA label carve-outs affect patent infringement risk for generics of C02DB drugs?
Label carve-outs can reduce method-of-use infringement risk when claims are regimen-based, shifting the fight toward formulation or process claims.
References (APA)
No sources were cited because no verified patent, Orange Book, FDA, or litigation dataset was provided in the input record.
More… ↓
